Review



cd99 flow cytometry miltenyi biotech  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd99 flow cytometry miltenyi biotech
    a , b CNCC differentiation was optimized using an ARID1B -wt control line. After 14 days, the cells exhibited the classic CNCC morphology and expressed the CNCC markers. P values are from two-sided Student’s t test. N = 3 biologically independent samples. Error bars display standard errors. c Time-course immunoblot conducted using Control Line-1 during CNCC differentiation shows that ARID1B is active in the first 7 days of the differentiation, with a peak of activity between day 5 and day 7. The ARID1B protein level strongly decreases after day 7. The experiment was repeated twice (the second replicate is shown in Fig. ). Marker bars display kDa. d , e Flow <t>cytometry</t> quantifying the expression of surface markers for pluripotency and CNCC differentiation in Control Line-1 and in the two patient lines. A large cell population is still pluripotent in both patients after 14 days ( d ). The patient lines also show reduced expression of CNCC surface markers after 14 days of differentiation relative to an ARID1B -wt control line at the same time point ( e ).
    Cd99 Flow Cytometry Miltenyi Biotech, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd99+flow+cytometry+miltenyi+biotech/CD99+Antibody%2C+anti-human%2C+REAfinity/pmc08578637-294-0-3
    Average 92 stars, based on 2 article reviews
    cd99 flow cytometry miltenyi biotech - by Bioz Stars, 2026-10
    92/100 stars

    Images

    1) Product Images from "Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B -related neurodevelopmental disorders"

    Article Title: Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B -related neurodevelopmental disorders

    Journal: Nature Communications

    doi: 10.1038/s41467-021-26810-x

    a , b CNCC differentiation was optimized using an ARID1B -wt control line. After 14 days, the cells exhibited the classic CNCC morphology and expressed the CNCC markers. P values are from two-sided Student’s t test. N = 3 biologically independent samples. Error bars display standard errors. c Time-course immunoblot conducted using Control Line-1 during CNCC differentiation shows that ARID1B is active in the first 7 days of the differentiation, with a peak of activity between day 5 and day 7. The ARID1B protein level strongly decreases after day 7. The experiment was repeated twice (the second replicate is shown in Fig. ). Marker bars display kDa. d , e Flow cytometry quantifying the expression of surface markers for pluripotency and CNCC differentiation in Control Line-1 and in the two patient lines. A large cell population is still pluripotent in both patients after 14 days ( d ). The patient lines also show reduced expression of CNCC surface markers after 14 days of differentiation relative to an ARID1B -wt control line at the same time point ( e ).
    Figure Legend Snippet: a , b CNCC differentiation was optimized using an ARID1B -wt control line. After 14 days, the cells exhibited the classic CNCC morphology and expressed the CNCC markers. P values are from two-sided Student’s t test. N = 3 biologically independent samples. Error bars display standard errors. c Time-course immunoblot conducted using Control Line-1 during CNCC differentiation shows that ARID1B is active in the first 7 days of the differentiation, with a peak of activity between day 5 and day 7. The ARID1B protein level strongly decreases after day 7. The experiment was repeated twice (the second replicate is shown in Fig. ). Marker bars display kDa. d , e Flow cytometry quantifying the expression of surface markers for pluripotency and CNCC differentiation in Control Line-1 and in the two patient lines. A large cell population is still pluripotent in both patients after 14 days ( d ). The patient lines also show reduced expression of CNCC surface markers after 14 days of differentiation relative to an ARID1B -wt control line at the same time point ( e ).

    Techniques Used: Western Blot, Activity Assay, Marker, Flow Cytometry, Expressing

    Related Articles

    Flow Cytometry:

    Article Title: Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B -related neurodevelopmental disorders
    Article Snippet: CD10 Flow Cytometry: Miltenyi Biotech 130-124-262. .. CD99 Flow Cytometry: Miltenyi Biotech 130-121-086. .. SSEA4 Flow Cytometry: Biolegend 330417.

    Article Title: Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B -related neurodevelopmental disorders
    Article Snippet: GAPDH western blot: Cell Signaling Technologies 5174 T. CD10 Flow Cytometry: Miltenyi Biotech 130-124-262. .. CD99 Flow Cytometry: Miltenyi Biotech 130-121-086. .. SSEA4 Flow Cytometry: Biolegend 330417.



    Similar Products

    cd99 flow cytometry miltenyi biotech  (Miltenyi Biotec)
    92
    Miltenyi Biotec cd99 flow cytometry miltenyi biotech
    a , b CNCC differentiation was optimized using an ARID1B -wt control line. After 14 days, the cells exhibited the classic CNCC morphology and expressed the CNCC markers. P values are from two-sided Student’s t test. N = 3 biologically independent samples. Error bars display standard errors. c Time-course immunoblot conducted using Control Line-1 during CNCC differentiation shows that ARID1B is active in the first 7 days of the differentiation, with a peak of activity between day 5 and day 7. The ARID1B protein level strongly decreases after day 7. The experiment was repeated twice (the second replicate is shown in Fig. ). Marker bars display kDa. d , e Flow <t>cytometry</t> quantifying the expression of surface markers for pluripotency and CNCC differentiation in Control Line-1 and in the two patient lines. A large cell population is still pluripotent in both patients after 14 days ( d ). The patient lines also show reduced expression of CNCC surface markers after 14 days of differentiation relative to an ARID1B -wt control line at the same time point ( e ).
    Cd99 Flow Cytometry Miltenyi Biotech, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd99+flow+cytometry+miltenyi+biotech/CD99+Antibody%2C+anti-human%2C+REAfinity/pmc08578637-294-0-3
    Average 92 stars, based on 1 article reviews
    cd99 flow cytometry miltenyi biotech - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    a , b CNCC differentiation was optimized using an ARID1B -wt control line. After 14 days, the cells exhibited the classic CNCC morphology and expressed the CNCC markers. P values are from two-sided Student’s t test. N = 3 biologically independent samples. Error bars display standard errors. c Time-course immunoblot conducted using Control Line-1 during CNCC differentiation shows that ARID1B is active in the first 7 days of the differentiation, with a peak of activity between day 5 and day 7. The ARID1B protein level strongly decreases after day 7. The experiment was repeated twice (the second replicate is shown in Fig. ). Marker bars display kDa. d , e Flow cytometry quantifying the expression of surface markers for pluripotency and CNCC differentiation in Control Line-1 and in the two patient lines. A large cell population is still pluripotent in both patients after 14 days ( d ). The patient lines also show reduced expression of CNCC surface markers after 14 days of differentiation relative to an ARID1B -wt control line at the same time point ( e ).

    Journal: Nature Communications

    Article Title: Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B -related neurodevelopmental disorders

    doi: 10.1038/s41467-021-26810-x

    Figure Lengend Snippet: a , b CNCC differentiation was optimized using an ARID1B -wt control line. After 14 days, the cells exhibited the classic CNCC morphology and expressed the CNCC markers. P values are from two-sided Student’s t test. N = 3 biologically independent samples. Error bars display standard errors. c Time-course immunoblot conducted using Control Line-1 during CNCC differentiation shows that ARID1B is active in the first 7 days of the differentiation, with a peak of activity between day 5 and day 7. The ARID1B protein level strongly decreases after day 7. The experiment was repeated twice (the second replicate is shown in Fig. ). Marker bars display kDa. d , e Flow cytometry quantifying the expression of surface markers for pluripotency and CNCC differentiation in Control Line-1 and in the two patient lines. A large cell population is still pluripotent in both patients after 14 days ( d ). The patient lines also show reduced expression of CNCC surface markers after 14 days of differentiation relative to an ARID1B -wt control line at the same time point ( e ).

    Article Snippet: CD99 Flow Cytometry: Miltenyi Biotech 130-121-086.

    Techniques: Western Blot, Activity Assay, Marker, Flow Cytometry, Expressing